The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17

Dirkje W. Sommeijer*, Christos S. Karapetis, John R. Zalcberg, Dongsheng Tu, Derek J. Jonker, John Simes, Niall Tebbutt, Desmond Yip, Timothy J. Price, Chris J. O'Callaghan

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science